This report describes a patient with ALK-rearranged non-small cell lung cancer who developed diffuse leptomeningeal carcinomatosis as the only “site” of progression after a prolonged response to crizotinib and who has been treated successfully with a second-generation ALK inhibitor alone for >15 months.
No takes yet. Share an insight, caveat, or question.
Ou et al. (2015) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: